Ehab El-Gabry - 23 Feb 2023 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role: Chief Medical Officer
Signature: /s/ Ehab El-Gabry, by Brian McKelligon, as Attorney-in-Fact
Issuer symbol: AKYA
Transactions as of: 23 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 27 Feb 2023, 16:02:49 UTC
Previous filing: 23 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKYA	Common Stock	Award	$0	+16,250		$0.000000	16,250	23 Feb 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKYA	Employee Stock Option (Right to Buy)	Award	$0	+32,500		$0.000000	32,500	23 Feb 2023	Common Stock	32,500	$12.30	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units shall vest in four (4) equal annual installments beginning on the first anniversary of the grant date and on each anniversary thereafter.
F2	Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.
F3	The options shall vest as follows: twenty-five percent (25%) shall vest on the first anniversary of the grant date with the remainder vesting in 36 equal monthly installments beginning on March 23, 2024.